The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It is quite a coincidence that the Co is renamed Arcturis Data Ltd when there is also Arctoris,
https://www.labiotech.eu/best-biotech/european-biotech-companies/
The potential is there.
GSK in patient data deal with American AI specialist to boost medicines pipeline
https://www.thetimes.co.uk/article/53237c04-4eee-11ed-b120-ca4f3ffbcdc5?shareToken=3d01df878bf046847ecfe4bdd0937c4a
We should get some update from the Co by some medium in the near future.
Sorry for mixing website.A very similar name im very similar business. I wasn’t paying proper attention.
Sorry forget that very similar name
It came up briefly. Looks like still in development
Is that a good sign?
Wonder what plays lay ahead for the renamed Co.
Check Companies House …. We have a new name
After all, whilst one division was heavily loss making, one division had a £22m profit with a NAV of £80 odd million. Then of course we have the loan note debt to consider and it looks like conversion into shares may take place in January depending on the holders of these loan notes That’s when the dilution occurs
I would suggest this Co under Alex Snow may have undergone / still undergoing rapid reorganisation. We know the board, now only consists of 4 and some senior management positions have also been axed. With Concentration on RWD, a completely revamped Co could emerge, worthy of a sale at a good price when the time is right.
Last year.
https://gatemore.com/wp-content/uploads/2021/07/Gatemore-Letter-to-Sensyne.pdf
Since then a lot has changed.
That was also published in May 22 at the height of negative publicity towards the company
I think you will find that is some ‘do good’ protest type organisation focused on ‘human rights’. We will see if Sensyne can carry the NHS with it. There is still a lot to ‘win’ here. It cannot be too long before we see the year end April 22 results published on Companies House website and perhaps some encouraging news on progress since Alex Snow has taken over. There is already some details with a statement from an August board meeting on cash status and divestment proceedings within the accounts for the divisions published at Companies House.
This doesn't sound good, let's see how this pans out?
https://www.bindmans.com/knowledge-hub/news/bindmans-advises-medconfidential-as-nhs-trusts-share-patient-data-with-sensyne-health/
That research was submitted here on 2nd https://arxiv.org/abs/2208.01607
Page 21 ‘acknowledgments’
A big research project released in August between Sensyne and Bayer. Also by the way there are a number of Sensyne employees working remotely from Germany from their LinkedIn info.
https://arxiv.org/pdf/2208.01607.pdf
Does this bode well for future collaboration?
If you read through the info already published with the divisions accounts already lodged with Companies House, an AGM is due. This note can be found with the info re Grant Thornton to continue as accountants and to ‘voted at upcoming AGM’ Hopefully we might have the date once the whole group accounts are published for the period ending April 22. The AGM may offer Snow the possibility of updating shareholders on progress since he took over.
Interesting to know if they continue to pursue the 140 million data records. Nasdaq listing once the company is back on its feet would be huge. This bottom drawer company might just be a saviour. Looking forward to the journey
From the info available from ‘about the Co ‘ in the ‘vacancies’ section of the Co website, seems they are growing the Real World Evidence team. All part of Snow’s realignment of the Co ? If so, there would indeed appear to be, som optimism for the future.
Some info on RWE here.
https://www.arbormetrix.com/blog/9-ways-real-world-evidence-is-changing-healthcare
Also looks like they may have changed their HR system with Bamboo HR now powering this department of the Co.
Looks like someone from the Co has been looking here ?? both Hudson and Tarassenko now removed from website as Co directors.
>Not sure what made me top up on 25th May 2022
Eternal optimism, haha! The optimism is still valid.